相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies
K. Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug - Drug Interactions
Maria Karlgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions
Maria Karlgren et al.
PHARMACEUTICAL RESEARCH (2012)
Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes
Karelle Menochet et al.
DRUG METABOLISM AND DISPOSITION (2012)
A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance
Carolina Saell et al.
DRUG METABOLISM AND DISPOSITION (2012)
In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine-Treated as Compared With Tacrolimus-Treated Renal Allograft Recipients
H. de Jonge et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction
Michael Gertz et al.
DRUG METABOLISM AND DISPOSITION (2011)
Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs
Jibin Li et al.
DRUG METABOLISM AND DISPOSITION (2011)
Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
Robert S. Foti et al.
DRUG METABOLISM AND DISPOSITION (2010)
Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin
Rune Amundsen et al.
DRUG METABOLISM AND DISPOSITION (2010)
Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data
Michael Gertz et al.
DRUG METABOLISM AND DISPOSITION (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
Annikka Kalliokoski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Grapefruit Juice-Drug Interaction Studies as a Method to Assess the Extent of Intestinal Availability: Utility and Limitations
Michael Gertz et al.
CURRENT DRUG METABOLISM (2008)
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin
Satoshi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Annikka Kalliokoski et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Annikka Kalliokoski et al.
PHARMACOGENETICS AND GENOMICS (2008)
Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions
Laura K. Hinton et al.
PHARMACEUTICAL RESEARCH (2008)
A prospective cross-over study comparing the pharmacokinetics of cyclosporine a and its metabolites after oral versus short-time intravenous cyclosporine a administration in pre-heart transplant patients
K. Lehle et al.
TRANSPLANTATION PROCEEDINGS (2007)
Intestinal permeability and its relevance for absorption and elimination
H. Lennernas
XENOBIOTICA (2007)
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3
Johannes Noe et al.
DRUG METABOLISM AND DISPOSITION (2007)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Mikko Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Trudy Rodgers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Correlations between calcineurin phosphatase inhibition and cyclosporine metabolites concentrations in kidney transplant recipients: Implications for immunoassays
N Karamperis et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes
Mia Hedman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers
F Kees et al.
THERAPEUTIC DRUG MONITORING (2006)
The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids
EM Persson et al.
PHARMACEUTICAL RESEARCH (2005)
Cyclosporine markedly raises the plasma concentrations of repaglinide
LI Kajosaari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat
A Treiber et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia
SD Campbell et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2004)
Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells
YY Chiu et al.
PHARMACEUTICAL RESEARCH (2003)
Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A
Y Shitara et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients
S Bauer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
The effects of portal shunts on intestinal cytochrome P450 3A activity
A Rostami-Hodjegan et al.
HEPATOLOGY (2002)
Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers
DI Min et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
